Ashley Gallagher, Associate Editor

Study results show that unvaccinated pregnant women with the disease are more likely to experience poor childbirth outcomes, even if they did not have severe respiratory problems.

Study results show health plans paid most of the drug costs, despite the lack of effect seen on COVID-19.

The World Health Organization issues a strong recommendation for baricitinib and a conditional one for sotrovimab.

The drug is the first and only injectable monoclonal antibody treatment for feline OA approved in the United States.

A new analysis suggests that boosters can provide ongoing prevention of death and hospitalization.

New research raises concerns about the commonly prescribed medications used to treat heart failure and high blood pressure, though investigators say patients should continue to take them.

New study results may help improve automated methods for detecting these spindles and correlating them with brain function, investigators say.

New study results suggest that severe depression and sexual dysfunction, in particular, can affect a woman's attention, language, orientation, recall, registration, and visuospatial skills.

When left untreated, this gut condition an inflamed can accelerate arterial disease, which can lead to a heart attack or stroke, according to research from UCLA.

In a subset of 537 patients receiving the IV therapy across 178 clinics, there was a 54% response rate and 30% remission rate.

Earlier analyses also demonstrated the same potential of BBV152 against SARS-CoV-2 alpha, beta, delta, zeta, and kappa.

These individuals also receive immunosuppressive drugs that often impair the immune responses to the vaccinations, study results show.

These mothers are approximately 17% less likely to die from cardiovascular disease, 14% less likely to develop coronary heart disease, and 12% less likely to suffer a stroke, the data show.

Compensation was a positive, while workload, management, and lack of work/life balance are the top reasons for dissatisfaction.

Ensovibep has met the primary endpoint of viral load reduction over 8 days in a phase 2 study, the companies said.

More aggressive competition and uptake could cause larger cuts, estimated at up to $124.5 billion between 2021 and 2025, according to the results of a RAND corporation analysis.

Analysis examines the impacted of expected trends in exposure to high blood sugar, low education levels, obesity, and smoking.

Although fewer than 1 in 5 adults with type 2 diabetes are meeting targets to reduce heart disease risk, available therapies can help when combined with new approaches that barriers to care.

A single shot protects for up to 6 months against breakthrough infections, hospitalizations, and intensive care unit admissions, Johnson & Johnson says.

Daridorexant (Quviviq, Idorsia Pharmaceuticals) is indicated for adults who experience difficulties with sleep onset and/or sleep maintenance.

About 48% of individuals experienced a complete or partial response when treated with pembrolizumab, and about two-thirds also had a response that lasted more than 3 years.

The agency previously granted a priority review for the supplemental new drug application and also approved the drug in 2015 to treat adults.

Despite best practice recommendations, prescriptions for acute pharyngitis are frequently not accompanied by testing, Epic Research data show.

Study results establish LAG-3 inhibition as therapeutically relevant third immune checkpoint pathway

New study results show that though men are more likely to have heart conditions, the impact on their memory and thinking skills is lower.

Results of an analysis from the University of Eastern Finland show that supplementation for 5 years had no effect on total mortality or the incidence of these diseases in older individuals.

The recommendations include full immunization, including third doses and/or any approved boosters.

Proof-of-contest is inexpensive and quantifies specific antigens from a drop of blood within minutes.

GeneSight Mental Health Monitor finds that many struggle to know the difference between teenage behavior and a mental health challenge.

Results of a separate analysis demonstrate that Johnson & Johnson’s booster generated a 41-fold increase in neutralizing antibodies and a 5-fold increase in T-cells against omicron.